Verastem's quest to develop drugs that block cell signaling pathways that cancer stem cells need to survive hits a major milestone in mid-2013, when it launches a 350-patient clinical trial of a potential companion biomarker test for its investigative mesothelioma drug treatment.
Qiagen disclosed it is seeking the FDA's blessing for a lung cancer-drug companion diagnostic, a test designed to screen patients for whom Boehringer Ingelheim's investigational treatment might work.
The companion diagnostic trend continues--and Ventana Medical Systems is involved yet again. This morning, Seattle Genetics and Takeda's Millennium unit announced that they are working with the Roche company on a companion diagnostic test for use in a study involving Adcetris.
Personalized medicine has been a popular topic in medical device and biopharma circles as of late. One company that has long had its eye on this area is Genoptix Medical Laboratory.
Colorectal cancer is a growing disease burden in the U.S., with roughly 140,000 new cases being diagnosed each year, according to the National Cancer Institute. Ann Arbor, MI-based Everist Genomics, which we profiled in our 5 innovative Michigan companies report last year, is looking to combat the disease and allow doctors to find it early enough to help patients.
We've been hearing a lot about companion diagnostics lately--especially as to how they can help save the healthcare system money by identifying those patients who might respond to certain treatments.
Siemens ($SI) is taking a big step into the hot companion diagnostic arena. The company, which makes a wide range of products, has announced separate pacts with ViiV Healthcare and Tocagen related to
It's a vexing problem that certain drugs with enormous benefit can also carry significant health risk. Case in point: Some patients who take the multiple sclerosis drug Tysabri experience improved
Another week, another big personalized medicine partnership announcement from Ventana Medical Systems. This time, the Roche unit said it will be working with Bayer Pharma on a molecular companion
In its latest of a series of companion diagnostic announcements, Roche's Ventana unit says it is collaborating with Pfizer ($PFE) and Cell Signaling Technology (CST) to develop a test identifying